Relmada Therapeutics RLMD
NASDAQ RLMD
$3.67 -0.10 (-2.52%)
As of: Oct 1, 2026 · 10:52 AM EDT

Relmada Therapeutics (RLMD) Net Margin (2012 - 2013)

Updated

Relmada Therapeutics' Net Margin was -877.66% in FY2013, down 725.89 percentage points from -151.77% in FY2012.

Analysis

Relmada Therapeutics (RLMD) Net Margin (2012 - 2013) Analysis & Trends

  • Per Business Quant data, Net Margin in earlier years was -151.77% in FY2012.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Margin (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 21.86%
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 21.27%
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -8.04%
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn 22.61%
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 18.81%
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 23.62%
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -134.51%
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -1.65%
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 32.99%
10 Relmada Therapeutics 402.15 Mn 402.15 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Nov 30, 2013 -776.97%
May 31, 2013 -3,073.34%
Feb 28, 2013 -176.73%
Nov 30, 2012 -419.73%
Aug 31, 2012 -569.57%
May 31, 2012 -620.25%
API Access

Relmada Therapeutics Net Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=net-margin&ticker=RLMD&period=max&api_key=YOUR_API_KEY